Research programme: age-related macular degeneration therapeutics - Dong-A ST

Drug Profile

Research programme: age-related macular degeneration therapeutics - Dong-A ST

Alternative Names: DA-3131

Latest Information Update: 12 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dong-A ST
  • Class Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Age-related macular degeneration

Highest Development Phases

  • Preclinical Age-related macular degeneration

Most Recent Events

  • 09 Oct 2015 Research programme: age-related macular degeneration therapeutics - Dong-A ST is available for licensing -http://en.donga-st.com/Pass.da?viewPath=/b02/licenseOut
  • 03 Sep 2015 Preclinical trials in Age-related macular degeneration in South Korea (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top